The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland
- PMID: 33604241
- PMCID: PMC7875822
- DOI: 10.1016/j.ymgmr.2021.100725
The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland
Abstract
Background: Gaucher disease (GD) is a rare inherited multiorgan disorder, yet a diagnosis can be significantly delayed due to a broad spectrum of symptoms and lack of disease awareness. Recently, the prototype of a GD point-scoring system (PSS) was established by the Gaucher Earlier Diagnosis Consensus (GED-C) initiative, and more recently, validated in Gaucher patients in UK. In our study, the original GED-C PSS was tested in Finnish GD patients. Furthermore, the feasibility of point scoring large electronic health record (EHR) data set by data mining to identify potential undiagnosed GD cases was evaluated.
Methods: This biobank study was conducted in collaboration with two Finnish biobanks. Five previously diagnosed Finnish GD patients and ~ 170,000 adult biobank subjects were included in the study. The original PSS was locally adjusted due to data availability issues and applied to the Finnish EHR data representing special health care recordings.
Results: All GD patients had high levels of the biomarker lyso-Gb1 and deleterious GBA mutations. One patient was a compound heterozygote with a novel variant, potentially pathogenic mutation. Finnish EHR data allowed the retrospective assessment of 27-30 of the 32 original GED-C signs/co-variables. Total point scores of GD patients were high but variable, 6-18.5 points per patient (based on the available data on 28-29 signs/co-variables per patient). All GD patients had been recorded with anaemia while only three patients had a record of splenomegaly. 0.72% of biobank subjects were assigned at least 6 points but none of these potential "GD suspects" had a point score as high as 18.5. Splenomegaly had been recorded for 0.25% of biobank subjects and was associated with variable point score distribution and co-occurring ICD-10 diagnoses.
Discussion: This study provides an indicative GED-C PSS score range for confirmed GD patients, also representing potential mild cases, and demonstrates the feasibility of scoring Finnish EHR data by data mining in order to screen for undiagnosed GD patients. Further prioritisation of the "GD suspects" with more developed algorithms and data-mining approaches is needed.
Funding: This study was funded by Shire (now part of Takeda).
Keywords: Biobank study; DBS, dried blood spot; EHR, Electronic health record; Electronic health record; GBA; GBA1/GBA, β-glucocerebrosidase gene; GD, Gaucher disease; GED-C, The Gaucher Earlier Diagnosis Consensus; Gaucher disease; Gaucher earlier diagnosis consensus point-scoring system; GlcCer, β-glucosylceramide; GlcCerase, β-glucosylceramidase; GlcSph/Lyso-Gb1, β-glucosylsphingosine; HDSF, Hospital District of Southwest Finland; Lyso-Gb1; NOHD, Northern Ostrobothnia Hospital District; PSS, Point-scoring system.
© 2021 The Authors.
Conflict of interest statement
CVF and KE are employed by Takeda (Stockholm, Sweden and Helsinki, Finland, respectively). AK and SR are employed by Auria Biobank and Biobank Borealis, respectively, which received reimbursement from Shire (now part of Takeda), for the work done at Auria/Borealis. IT, KU, and MIL are employed by Medaffcon Oy (Espoo, Finland) which received funding from Shire (now part of Takeda), for conducting the study. MJS reports personal consultancy fees and travel grants from Shire (now part of Takeda) during the study, as well as grant support, paid to his institution, from several foundations for research outside the submitted work.
Figures
Similar articles
-
Screening for potential undiagnosed Gaucher disease patients: Utilisation of the Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS) in conjunction with electronic health record data, tissue specimens, and small nucleotide polymorphism (SNP) genotype data available in Finnish biobanks.Mol Genet Metab Rep. 2022 Aug 27;33:100911. doi: 10.1016/j.ymgmr.2022.100911. eCollection 2022 Dec. Mol Genet Metab Rep. 2022. PMID: 36092251 Free PMC article.
-
Assessing the diagnostic utility of the Gaucher Earlier Diagnosis Consensus (GED-C) scoring system using real-world data.Orphanet J Rare Dis. 2024 Feb 16;19(1):71. doi: 10.1186/s13023-024-03042-y. Orphanet J Rare Dis. 2024. PMID: 38365689 Free PMC article.
-
Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.Intern Med J. 2019 May;49(5):578-591. doi: 10.1111/imj.14156. Intern Med J. 2019. PMID: 30414226 Free PMC article. Review.
-
Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?Int J Mol Sci. 2022 Jan 30;23(3):1627. doi: 10.3390/ijms23031627. Int J Mol Sci. 2022. PMID: 35163551 Free PMC article.
-
Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.Orphanet J Rare Dis. 2023 Feb 13;18(1):27. doi: 10.1186/s13023-023-02623-7. Orphanet J Rare Dis. 2023. PMID: 36782327 Free PMC article. Review.
Cited by
-
Screening for potential undiagnosed Gaucher disease patients: Utilisation of the Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS) in conjunction with electronic health record data, tissue specimens, and small nucleotide polymorphism (SNP) genotype data available in Finnish biobanks.Mol Genet Metab Rep. 2022 Aug 27;33:100911. doi: 10.1016/j.ymgmr.2022.100911. eCollection 2022 Dec. Mol Genet Metab Rep. 2022. PMID: 36092251 Free PMC article.
-
Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review.J Clin Med. 2022 Dec 22;12(1):85. doi: 10.3390/jcm12010085. J Clin Med. 2022. PMID: 36614898 Free PMC article. Review.
-
Assessing the diagnostic utility of the Gaucher Earlier Diagnosis Consensus (GED-C) scoring system using real-world data.Orphanet J Rare Dis. 2024 Feb 16;19(1):71. doi: 10.1186/s13023-024-03042-y. Orphanet J Rare Dis. 2024. PMID: 38365689 Free PMC article.
-
Obstacles to Early Diagnosis of Gaucher Disease.Ther Clin Risk Manag. 2025 Jan 25;21:93-101. doi: 10.2147/TCRM.S388266. eCollection 2025. Ther Clin Risk Manag. 2025. PMID: 39882275 Free PMC article. Review.
-
Patient-Patient Similarity-Based Screening of a Clinical Data Warehouse to Support Ciliopathy Diagnosis.Front Pharmacol. 2022 Mar 25;13:786710. doi: 10.3389/fphar.2022.786710. eCollection 2022. Front Pharmacol. 2022. PMID: 35401179 Free PMC article.
References
-
- Stirnemann J., Belmatoug N., Camou F., Serratrice C., Froissart R., Caillaud C., Levade T., Astudillo L., Serratrice J., Brassier A., Rose C., Billette de Villemeur T., Berger M. A review of Gaucher disease pathophysiology, clinical presentation and treatments. IJMS. 2017;18:441. doi: 10.3390/ijms18020441. - DOI - PMC - PubMed
-
- Aerts J.M.F.G., Kallemeijn W.W., Wegdam W., Joao Ferraz M., van Breemen M.J., Dekker N., Kramer G., Poorthuis B.J., Groener J.E.M., Cox-Brinkman J., Rombach S.M., Hollak C.E.M., Linthorst G.E., Witte M.D., Gold H., van der Marel G.A., Overkleeft H.S., Boot R.G. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J. Inherit. Metab. Dis. 2011;34:605–619. doi: 10.1007/s10545-011-9308-6. - DOI - PMC - PubMed
-
- Nilsson O., Månsson J.-E., Håk̈ansson G., Svennerholm L. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of gaucher’s disease. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1982;712:453–463. doi: 10.1016/0005-2760(82)90272-7. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources